Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antitope Ltd.

Division of Abzena Ltd./PolyTherics Ltd.
www.antitope.co.uk

Latest From BioWest Therapeutics Inc.

Ritter Pharmaceuticals Appoints CMO

Ritter Pharmaceuticals, Inc. has appointed AnnKatrin Petersen-Jappelli chief medical officer (CMO). Petersen-Jappelli, who is currently on the board of Salgomed Inc., brings 25 years of drug development experience to Ritter and was previously advisor, scientific research and clinical development leader of a Phase III program at Santarus Inc. Prior to this, she was vice-president of product development at MIGENIX Inc. and has held development positions at Pfizer, Sandoz (Novartis) and Agouron Pharmaceuticals.

Companies

Market Insight - Hepatitis C: in search of a breakthrough

Infection with the hepatitis C virus (HCV) represents an important healthcare problem worldwide. Current estimates suggest that globally about 170 million people, representing approximately 3% of the world's population, are chronically infected, and are at risk of developing liver cirrhosis and/or hepatocellular carcinoma. Estimates indicate that in the US, three to four million people are infected annually. The prevalence of HCV-related disease is increasing, but no vaccine is yet available.

Infectious Diseases Cancer

Selected Start-Ups (9/04)

In Vivo briefly summarizes the technologies of these recently founded companies: Alimera Sciences Ic., CellCentric Ltd., NovoStent Corp., Plantacor Inc., Sadra Medical Inc. and Strata Pharmaceuticals Inc.

Effecting New Antibiotics, Part I

Gone are the days of random screening for new antibiotics. Now, thanks to molecular biology and genomics, start-up companies have a better sense of the mechanisms of infection. The firms think they've found novel ways to interfere with pathogens, including those resistant to current drugs.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Abzena Ltd.
  • Senior Management
  • Matthew Baker, PhD, CEO & CSO
    Neil Butt, PhD, VP, Bus. Dev.
  • Contact Info
  • Antitope Ltd.
    Phone: (0) 1223 496190
    Babraham Research Campus
    Babraham
    Cambridge, CB22 3AT
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register